Local and systemic methotrexate in management of caesarean scar pregnancy
- PMID: 39637522
- DOI: 10.1016/j.ejogrb.2024.11.033
Local and systemic methotrexate in management of caesarean scar pregnancy
Abstract
Study objective: The aim is to analyze the management of cesarean scar pregnancy (CSP) based on local and systemic Methotrexate, a protocol implemented in a referral center.
Design: This is an observational, retrospective, monocentric, cohort study with a description of the local protocol, treatment results and tolerance profile. Design Classification III.
Setting: Tertiary Referral center.
Patients: All patients with CSP, confirmed by a reference ultrasound, without severity criteria requiring emergency surgery, between March 2015 to August 2022 were consecutively included.
Interventions: All patients were treated by an Echo-guided trans-vaginal aspiration of the gestational sac followed by a local injection of Methotrexate 1 mg/kg under general anesthesia combined with Mifepristone and followed by an injection of 1 mg/kg within 2 days.
Measurement and main finding: We included 35 patients with a mean hCG level of 28 872 UI/l ± 38063 UI/l and a mean gestational age of 6.8 ± 1.6 weeks of gestation. All patients were managed effectively with a good reduction in hCG serum levels. The mean duration of hCG negativation was 66 ± 38 days after the start of management. Only one patient who had received the department's Methotrexate protocol required a second line of treatment. Among major complications, 2 patients experienced hemorrhagic shock which resolved without recourse to hemostasis hysterectomy. The success rate defined by the absence of recourse to secondary treatment was therefore 91.4 %. Among minor complications, the main complication was methotrexate-induced hepatic cytolysis in 7 patients (20 %). Nine women (26 %) required secondary hysteroscopic resection of trophoblastic retention. Twenty-one patients (60 %) had an ultrasound diagnosis of caesarean scar defect (CSD) after CSP management.
Conclusion: The combination of transvaginal ultrasound-guided local MTX, Mifepristone and systemic MTX appears to be an effective treatment protocol for patients with CSP.
Keywords: Cesarean section scar pregnancy; Medical Treatment; Methotrexate.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical